New Look Medigene Plots Immune-Oncology Future With New CEO

It has been two years since Medigene made its "transformative" acquisition of a small German company called Trianta Immunotherapies. Following a series of recent divestments, Medigene is now a fully immune-oncology focused biotech, and Trianta's former CEO Dolores Schendel – who has been Medigene's CSO since the acquisition - is about to take over from Frank Mathias as Medigene's CEO.